Vivacta Bio Raises $50M+ Series A Funding for GT801 CAR-T Gene Therapy Development

Key Takeaways

• Vivacta Bio secured over $50 million in Series A and A+ funding rounds to advance CAR-T gene therapy programs
• Lead candidate GT801 shows promising safety and efficacy in early trials for blood cancers and autoimmune diseases
• Funding will accelerate clinical development of in vivo CAR-T platform technology

---

Vivacta Biotechnology (Shanghai) Co., Ltd. announced the completion of Series A and Series A+ financing rounds totaling over $50 million, marking a significant milestone for the innovative biotechnology company focused on revolutionizing CAR-T cell therapies.

Revolutionary In Vivo CAR-T Approach

Vivacta Bio is developing next-generation CAR-T therapies that can be administered directly in vivo, potentially eliminating the complex and costly ex vivo cell manufacturing process required by current CAR-T treatments. This approach could dramatically reduce treatment costs and improve patient access to CAR-T therapies.

GT801 Shows Clinical Promise

The company’s lead candidate, GT801, has demonstrated encouraging safety and efficacy profiles in early-stage clinical studies. The therapy is being evaluated for treating hematological malignancies (blood cancers) and autoimmune diseases, representing a broad therapeutic potential.

Unlike traditional CAR-T therapies that require extracting a patient’s T cells, genetically modifying them in a laboratory, and reinfusing them, GT801’s in vivo approach could deliver genetic modifications directly to T cells within the patient’s body.

Market Impact and Investment Significance

The substantial funding round reflects growing investor confidence in next-generation CAR-T technologies. The global CAR-T cell therapy market is projected to reach $20 billion by 2030, driven by expanding applications beyond oncology into autoimmune disorders.

This financing will enable Vivacta to advance GT801 through clinical development phases and expand its pipeline of in vivo CAR-T candidates. The company’s platform technology could address key limitations of current CAR-T therapies, including manufacturing complexity, treatment delays, and high costs that limit patient access.

Future Outlook

With this funding secured, Vivacta Bio is positioned to accelerate clinical trials and potentially bring more accessible CAR-T therapies to patients worldwide. The company’s innovative approach could transform how CAR-T therapies are delivered, making these powerful treatments available to broader patient populations.

---

Frequently Asked Questions

What makes GT801 different from existing CAR-T therapies?

GT801 is designed as an in vivo CAR-T therapy, meaning it can genetically modify T cells directly inside the patient’s body, potentially eliminating the need for complex laboratory cell manufacturing required by current CAR-T treatments.

When will GT801 be available to patients?

GT801 is currently in early clinical studies. The new $50+ million funding will help advance the therapy through clinical development phases, but regulatory approval and commercial availability are still several years away.

What conditions could GT801 treat?

GT801 is being evaluated for hematological malignancies (blood cancers) and autoimmune diseases. Early clinical studies have shown promising safety and efficacy profiles for both therapeutic areas.